Trial Profile
Effect of nintedanib on cough and health related quality of life in patients with idiopathic pulmonary fibrosis measured with disease and symptom specific questionnaires.
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 04 Jan 2017
Price :
$35
*
At a glance
- Drugs Nintedanib (Primary)
- Indications Idiopathic pulmonary fibrosis
- Focus Therapeutic Use
- 04 Jan 2017 New trial record